	US 12,291,723 B2
	T-cell receptor-deficient T cell compositions
Charles L. Sentman, West Lebanon, NH (US)
Assigned to THE TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed by THE TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed on Jun. 22, 2020, as Appl. No. 16/907,374.
Application 16/907,374 is a division of application No. 15/815,261, filed on Nov. 16, 2017, granted, now 10,689,617.
Application 15/815,261 is a division of application No. 15/383,717, filed on Dec. 19, 2016, granted, now 9,821,011, issued on Nov. 21, 2017.
Application 15/383,717 is a division of application No. 14/934,256, filed on Nov. 6, 2015, granted, now 9,957,480, issued on May 1, 2018.
Application 14/934,256 is a division of application No. 13/502,978, granted, now 9,181,527, issued on Nov. 10, 2015, previously published as PCT/US2010/054846, filed on Oct. 29, 2010.
Claims priority of provisional application 61/255,980, filed on Oct. 29, 2009.
Prior Publication US 2020/0385677 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 35/12 (2015.01)

CPC C12N 5/0636 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4632 (2023.05); A61K 39/464429 (2023.05); A61K 2035/124 (2013.01); A61K 2039/585 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/59 (2023.05); C12N 2501/515 (2013.01); C12N 2510/02 (2013.01); C12N 2511/00 (2013.01)]

5 Claims

1. A composition comprising a pool of recombinant primary human T cells or progeny thereof:

(i) have been modified to functionally impair and/or to reduce expression of the endogenous T cell receptor (TCR), and

(ii) have been further modified to express at least one functional exogenous non-TCR receptor comprising (1) a ligand binding domain which binds to a ligand expressed by tumor cells of the treated subject and (2) a signaling domain,

wherein said pool of recombinant modified human T cells or progeny thereof express one or more ligand binding domains which bind to an antigen expressed by tumor cells of the treated subject.